ADPT - Adaptive Biotechnologies Corp
IEX Last Trade
4.71
0.040 0.849%
Share volume: 743,471
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$4.67
0.04
0.86%
View ratios
Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
Report Date | 2022-11-03 | 2023-02-14 | 2023-05-03 | 2023-08-02 | 2023-11-09 | 2024-02-29 | 2024-05-07 | 2024-08-01 | |
Assets | |||||||||
Total Assets | 884.208 M | 856.617 M | 791.463 M | 764.540 M | 717.682 M | 661.134 M | 620.323 M | 584.872 M | |
Current Assets | 564.380 M | 562.146 M | 501.333 M | 476.809 M | 435.237 M | 410.188 M | 374.034 M | 351.552 M | |
Inventories | 17.345 M | 14.453 M | 19.874 M | 18.960 M | 19.490 M | 14.448 M | 13.291 M | 13.214 M | |
Other Current Assets | 12.407 M | 9.440 M | 9.792 M | 9.074 M | 13.404 M | 11.370 M | 9.850 M | 10.848 M | |
Short Term Investments | 12.407 M | 9.440 M | 9.792 M | 9.074 M | 13.404 M | 11.370 M | 9.850 M | 10.848 M | |
Total Receivables | 26.549 M | 40.057 M | 30.972 M | 31.545 M | 31.211 M | 37.969 M | 42.021 M | 35.610 M | |
Current Cash | 508.079 M | 498.196 M | 440.695 M | 417.230 M | 371.132 M | 346.401 M | 308.872 M | 291.880 M | |
Total Non-current Assets | 319.828 M | 294.471 M | 290.130 M | 287.731 M | 282.445 M | 250.946 M | 246.289 M | 233.320 M | |
Property Plant Equipment | 86.662 M | 83.447 M | 81.294 M | 79.390 M | 76.749 M | 68.227 M | 65.260 M | 55.418 M | |
Other Assets | 2.202 M | 2.064 M | 2.181 M | 3.352 M | 2.983 M | 3.591 M | 3.390 M | 3.152 M | |
Intangible Assets | 7.256 M | 6.827 M | 6.408 M | 5.985 M | 5.557 M | 5.128 M | 4.705 M | 4.281 M | |
Goodwill | 118.972 M | 118.972 M | 118.972 M | 118.972 M | 118.972 M | 118.972 M | 118.972 M | 118.972 M | |
Liabilities and shareholders’ equity | |||||||||
Total Liabilities and shareholders’ equity | 884.208 M | 856.617 M | 791.463 M | 764.540 M | 717.682 M | 661.134 M | 620.323 M | 584.872 M | |
Total liabilities | 396.368 M | 392.452 M | 367.443 M | 368.504 M | 355.950 M | 352.735 M | 345.410 M | 343.269 M | |
Total current liabilities | 104.018 M | 109.788 M | 90.101 M | 95.335 M | 93.298 M | 88.015 M | 82.952 M | 88.126 M | |
Accounts Payable | 4.163 M | 8.084 M | 6.333 M | 9.163 M | 4.483 M | 7.719 M | 12.170 M | 9.867 M | |
Other liabilities | 191.855 M | 183.959 M | 180.916 M | 179.062 M | 170.923 M | 175.453 M | 175.705 M | 170.946 M | |
Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Other liabilities | 191.855 M | 183.959 M | 180.916 M | 179.062 M | 170.923 M | 175.453 M | 175.705 M | 170.946 M | |
Minority interest | -26.000 K | -67.000 K | -68.000 K | -69.000 K | -95.000 K | -121.000 K | -147.000 K | -173.000 K | |
Total Shareholder equity | 487.840 M | 464.165 M | 424.020 M | 396.036 M | 361.732 M | 308.399 M | 274.913 M | 241.603 M | |
Common stock | 142.929 M | 143.074 M | 143.511 M | 144.398 M | 144.705 M | 144.919 M | 145.788 M | 147.414 M | |
Retained earnings | -878.954 M | -919.082 M | -976.781 M | -1.025 B | -1.075 B | -1.144 B | -1.192 B | -1.238 B |